BioGaia makes Further Investment in MetaboGen
01 Dec 2016 --- BioGaia has today made a further investment in MetaboGen AB after the company first reported its decision to invest SEK 12 million into MetaboGen AB in 2014.
The investment was set to be made over a two-year period, with the first investment of SEK 4 million taking place in December 2014 and the second in December 2015.
As MetaboGen has reached the agreed milestones, the last investment of SEK 4 million was made today.
BioGaia now owns 36% of the share capital of MetaboGen.
MetaboGen is a research company, which was founded in 2011 in Gothenburg by Professor Fredrik Bäckhed at the University of Gothenburg and Professor Jens B Nielsen at Chalmers University of Technology together with GU Holding, which commercializes research results and develops companies linked to the University of Gothenburg.
MetaboGen researches metagenomics, the research intensive and fast developing field of gene sequencing of all genes in the microbial communities of for example the human gut, to find previously unknown members and patterns of the microbial diversity related to health and disease.
The companies aim to develop new treatments and products for different metabolic and other microbial associated diseases by influencing large parts of the microbiota.
